Scientists at UC San Francisco have developed a revolutionary cancer treatment that precisely targets tumors with radiation ...

Researchers, led by the University of Melbourne's Professor Laura Mackay, a Laboratory Head and Immunology Theme Leader at ...

A groundbreaking study has uncovered how specific genetic mutations influence cancer treatment outcomes -- insights that could help doctors tailor treatments more effectively. The largest study of its ...

Noah S. Kalman, MD, MBA, discusses the evolving role of molecular and genetic testing in thyroid cancer management.

An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic ...

Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the U.S. Food ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

The status has been given to the B7-H3-targeted ... therapy. The FDA previously designated the ADC as a breakthrough drug for relapsed or refractory extensive-stage small-cell lung cancer (SCLC ...

AstraZeneca and partner Daiichi Sankyo have their first phase 3 data for TROP2-targeting antibody-drug conjugate ... small cell lung cancer (NSCLC) treated with at least one prior therapy when ...

A clinical study testing a Pliant Therapeutics drug once considered a promising prospect for treating a fatal lung disorder is ... 3 study designed to evaluate treatment with bexotegrast for ...

Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a ... nerandomilast as a treatment for PPF, a type of interstitial lung disease.

Palliative care for young adults with colorectal cancer reduced invasive procedures, costs and increased DNR orders. Dr. Filippo Pietrantonio discusses OrigAMI-1 trial data which assessed Rybrevant in ...